Progress in Paroxysmal Nocturnal Hemoglobinuria Treatment: The Impact of New Data From ASH 2024 Ilene Weitz, MDDisclosures January 02, 2025 0Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024....
Following its acquisition by Pfizer in October 2022,6 Global Blood Therapeutics (GBT) continues to make progress toward optimizing treatment for SCD. The $5.4 billion acquisition will enhance GBT’s ability to deliver life-changing treatments for historically underserved patient communities,7 while for ...
While most cases of AML appear de novo in a patient who was previously healthy, it can progress from other conditions, such as MDS or myeloproliferative disorders. Researchers from the John H. Stroger, Jr Hospital of Cook County in Chicago, Illinois, and the University of Illinois College of...
The 52nd Annual Meeting of the American Society of Hematology showcased the results from some of the cutting edge research related to management of multiple myeloma (MM). Significant progress has been made in the treatment of patients with myeloma during the past decade and patients are living ...
“These promising data at ASH represent important progress, and I am encouraged by the next wave of potential advances across a diverse range of targets and platforms, which may provide treating physicians with...
“We are unique in our approach to optimizing many aspects of a cell therapy for patient benefit. The advancement of CRG-023 underscores our sophisticated cell-engineering capabilities and importantly, our pipeline potential in next-generation CAR T-cell therapies that are designed to deliver multiple...
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently ...
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead a...
Secondary Malignanciesmay develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing. Effects on Abi...